DiaMedica Therapeutics, Inc.

  • Home
  • Our Focus
    • Overview
    • Literature & Publications
  • Pipeline
    • Overview
    • Preeclampsia
    • Acute Ischemic Stroke
  • Clinical Trials
    • Overview
    • Preeclampsia
    • Acute Ischemic Stroke
  • ReMEDy2 Trial
    • Overview
    • About ReMEDy2
    • Stroke Disease
    • For Physicians
    • Trial Locations
  • About DiaMedica
    • Overview
    • Leadership
    • Careers
    • Contact
  • Investors Relations
    • Overview
    • Press Releases
    • Events & Presentations
    • Stock Data
    • Analyst Coverage
    • Financial Reports & SEC Filings
    • Governance
    • Resources

Press Releases

Investors Relations

Investors Relations

  • Overview
  • Press Releases
  • Events & Presentations
  • Stock Data
    • Nasdaq Quote
    • Charts
    • Historical Data
  • Analyst Coverage
  • Financial Reports & SEC Filings
    • SEC Filings
    • Annual Reports
    • Tax Information (PFIC)
  • Governance
    • Board of Directors
    • Board Committees
    • Governance Documents
  • Resources
    • Investor Contact
    • FAQ
    • Share Consolidation Instructions
    • Email Alerts
Aug 06, 2025 8:00am EDT

DiaMedica Therapeutics Appoints Julie Krop, MD, as Chief Medical Officer

Aug 05, 2025 4:15pm EDT

DiaMedica Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Business Update August 13, 2025

Jul 23, 2025 4:30pm EDT

DiaMedica Therapeutics Announces Closing of $30.1 Million Private Placement

Jul 21, 2025 8:00am EDT

DiaMedica Therapeutics Raises $30 Million in Private Placement to Accelerate Industry Leading Preeclampsia and Fetal Growth Restriction Pipeline

Jul 17, 2025 8:00am EDT

DiaMedica Therapeutics Reports Positive Interim Phase 2 Preeclampsia Results: Statistically Significant Reductions in Blood Pressure and No Placental Transfer

Jun 24, 2025 8:30am EDT

DiaMedica Therapeutics Announces Inclusion in the Russell 2000® and Russell 3000® Indexes

May 22, 2025 8:30am EDT

DiaMedica Therapeutics to Present at Jefferies Global Healthcare Conference 2025

May 19, 2025 9:00am EDT

DiaMedica Therapeutics Announces Key Opinion Leader Webinar on DM199 (Rinvecalinase Alfa) for the Treatment of Preeclampsia

May 14, 2025 4:30pm EDT

DiaMedica Therapeutics Announces Poster Presentation at European Stroke Organisation Conference – ESOC 2025

May 13, 2025 4:30pm EDT

DiaMedica Therapeutics Reports First Quarter 2025 Financial Results And Provides Business Highlights

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • …17
  • Next
RSS
  • Email Alerts
  • Contacts
  • RSS News Feed
© 2025 DiaMedica Therapeutics, Inc. All Rights Reserved.
Twitter LinkedIn
Privacy Policy Disclaimer Sitemap